Resveratrol attenuates acute kidney injury by inhibiting death receptor‑mediated apoptotic pathways in a cisplatin‑induced rat model

Hao,Qiufa; Xiao,Xiaoyan; Zhen,Junhui; Feng,Jinbo; Song,Chun; Jiang,Bei; Hu,Zhao

doi:10.3892/mmr.2016.5714

Resveratrol attenuates acute kidney injury by inhibiting death receptor‑mediated apoptotic pathways in a cisplatin‑induced rat model

Authors:
- Qiufa Hao
- Xiaoyan Xiao
- Junhui Zhen
- Jinbo Feng
- Chun Song
- Bei Jiang
- Zhao Hu
View Affiliations

Affiliations: Department of Nephrology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China, Department of Pathology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China, Institute of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China, Department of Pharmacy, Shandong University School of Pharmacy, Jinan, Shandong 250012, P.R. China
Published online on: September 5, 2016 https://doi.org/10.3892/mmr.2016.5714
Pages: 3683-3689
Copyright: © Hao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acute kidney injury is a clinical syndrome characterized by a loss of renal function and acute tubular necrosis. Resveratrol exerts a wide range of pharmacological effects based on its anti‑inflammatory, antioxidant and cytoprotective properties. The present study aimed to evaluate whether resveratrol attenuates acute kidney injury in a cisplatin‑induced rat model and to investigate the potential mechanisms involved. Rats were randomly divided into four treatment groups: control, cisplatin, resveratrol, and cisplatin plus resveratrol. Rats exposed to cisplatin displayed acute kidney injury, identified by analysis of renal function and histopathological observation. Resveratrol significantly ameliorated the increased serum creatinine, blood urea nitrogen, renal index and histopathological damage induced by cisplatin. Furthermore, compared with untreated control animals, cisplatin lead to significantly increased expression of Fas ligand, tumor necrosis factor‑α (TNF‑α), caspase‑8 and Bcl‑2 associated protein X apoptosis regulator (Bax), and decreased expression of anti‑apoptosis regulators, BH3 interacting domain death agonist (BID) and B cell lymphoma 2 apoptosis regulator (Bcl‑2). Administration of resveratrol significantly reversed the cisplatin‑induced alteration in these apoptosis‑associated proteins. In conclusion, these findings suggest that resveratrol attenuates cisplatin‑induced acute kidney injury through inactivation of the death receptor‑mediated apoptotic pathway, and may provide a new therapeutic strategy to ameliorate the process of acute kidney injury.

View Figures

View References

1	Linkermann A, Chen G, Dong G, Kunzendorf U, Krautwald S and Dong Z: Regulated cell death in AKI. J Am Soc Nephrol. 25:2689–2701. 2014. View Article : Google Scholar : PubMed/NCBI
2	Bellomo R, Kellum JA and Ronco C: Acute kidney injury. Lancet. 380:756–766. 2012. View Article : Google Scholar : PubMed/NCBI
3	Faubel S, Chawla LS, Chertow GM, Goldstein SL, Jaber BL and Liu KD; Acute Kidney Injury Advisory Group of the American Society of Nephrology: Ongoing clinical trials in AKI. Clin J Am Soc Nephrol. 7:861–873. 2012. View Article : Google Scholar : PubMed/NCBI
4	Lameire NH, Bagga A, Cruz D, De Maeseneer J, Endre Z, Kellum JA, Liu KD, Mehta RL, Pannu N, Van Biesen W and Vanholder R: Acute kidney injury: An increasing global concern. Lancet. 382:170–179. 2013. View Article : Google Scholar : PubMed/NCBI
5	dos Santos NA, Carvalho Rodrigues MA, Martins NM and dos Santos AC: Cisplatin-induced nephrotoxicity and targets of nephroprotection: An update. Arch Toxicol. 86:1233–1250. 2012. View Article : Google Scholar : PubMed/NCBI
6	Sánchez-González PD, López-Hernández FJ, López-Novoa JM and Morales AI: An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity. Crit Rev Toxicol. 41:803–821. 2011. View Article : Google Scholar : PubMed/NCBI
7	Karasawa T and Steyger PS: An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol Lett. 237:219–227. 2015. View Article : Google Scholar : PubMed/NCBI
8	Pabla N and Dong Z: Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int. 73:994–1007. 2008. View Article : Google Scholar : PubMed/NCBI
9	Ashkenazi A and Dixit VM: Death receptors: Signaling and modulation. Science. 281:1305–1308. 1998. View Article : Google Scholar : PubMed/NCBI
10	Zou P, Song J, Jiang B, Pei F, Chen B, Yang X, Liu G and Hu Z: Epigallocatechin-3-gallate protects against cisplatin nephrotoxicity by inhibiting the apoptosis in mouse. Int J Clin Exp Pathol. 7:4607–4616. 2014.PubMed/NCBI
11	Linkermann A, Himmerkus N, Rölver L, Keyser KA, Steen P, Bräsen JH, Bleich M, Kunzendorf U and Krautwald S: Renal tubular Fas ligand mediates fratricide in cisplatin-induced acute kidney failure. Kidney Int. 79:169–178. 2011. View Article : Google Scholar
12	Tsuruya K, Ninomiya T, Tokumoto M, Hirakawa M, Masutani K, Taniguchi M, Fukuda K, Kanai H, Kishihara K, Hirakata H and Iida M: Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. Kidney Int. 63:72–82. 2003. View Article : Google Scholar
13	Tsuruya K, Tokumoto M, Ninomiya T, Hirakawa M, Masutani K, Taniguchi M, Fukuda K, Kanai H, Hirakata H and Iida M: Antioxidant ameliorates cisplatin-induced renal tubular cell death through inhibition of death receptor-mediated pathways. Am J Physiol Renal Physiol. 285:F208–F218. 2003. View Article : Google Scholar : PubMed/NCBI
14	Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH and Peter ME: Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17:1675–1687. 1998. View Article : Google Scholar : PubMed/NCBI
15	Wang X and Parrish AR: Loss of α(E)-catenin promotes Fas mediated apoptosis in tubular epithelial cells. Apoptosis. 20:921–929. 2015. View Article : Google Scholar : PubMed/NCBI
16	Luo X, Budihardjo I, Zou H, Slaughter C and Wang X: Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 94:481–490. 1998. View Article : Google Scholar : PubMed/NCBI
17	Nogae S, Miyazaki M, Kobayashi N, Saito T, Abe K, Saito H, Nakane PK, Nakanishi Y and Koji T: Induction of apoptosis in ischemia-reperfusion model of mouse kidney: Possible involvement of Fas. J Am Soc Nephrol. 9:620–631. 1998.PubMed/NCBI
18	Schelling JR, Nkemere N, Kopp JB and Cleveland RP: Fas-dependent fratricidal apoptosis is a mechanism of tubular epithelial cell deletion in chronic renal failure. Lab Invest. 78:813–824. 1998.PubMed/NCBI
19	Malhotra A, Bath S and Elbarbry F: An organ system approach to explore the antioxidative, anti-inflammatory and cytoprotective actions of resveratrol. Oxid Med Cell Longev. 2015:8039712015. View Article : Google Scholar
20	Kitada M and Koya D: Renal protective effects of resveratrol. Oxid Med Cell Longev. 2013:5680932013. View Article : Google Scholar :
21	Catalgol B, Batirel S, Taga Y and Ozer NK: Resveratrol: French paradox revisited. Front Pharmacol. 3:1412012. View Article : Google Scholar : PubMed/NCBI
22	Kanamori H, Takemura G, Goto K, Tsujimoto A, Ogino A, Takeyama T, Kawaguchi T, Watanabe T, Morishita K, Kawasaki M, et al: Resveratrol reverses remodeling in hearts with large, old myocardial infarctions through enhanced autophagy-activating AMP kinase pathway. Am J Pathol. 182:701–713. 2013. View Article : Google Scholar : PubMed/NCBI
23	Turner RS, Thomas RG, Craft S, van Dyck CH, Mintzer J, Reynolds BA, Brewer JB, Rissman RA, Raman R and Aisen PS; Alzheimer's Disease Cooperative Study: A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 85:1383–1391. 2015. View Article : Google Scholar : PubMed/NCBI
24	Kim DH, Jung YJ, Lee JE, Lee AS, Kang KP, Lee S, Park SK, Han MK, Lee SY, Ramkumar KM, et al: SIRT1 activation by resveratrol ameliorates cisplatin-induced renal injury through deacetylation of p53. Am J Physiol Renal Physiol. 301:F427–F435. 2011. View Article : Google Scholar : PubMed/NCBI
25	Oi N, Jeong CH, Nadas J, Cho YY, Pugliese A, Bode AM and Dong Z: Resveratrol, a red wine polyphenol, suppresses pancreatic cancer by inhibiting leukotriene A₄hydrolase. Cancer Res. 70:9755–9764. 2010. View Article : Google Scholar : PubMed/NCBI
26	Crandall JP, Oram V, Trandafirescu G, Reid M, Kishore P, Hawkins M, Cohen HW and Barzilai N: Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci. 67:1307–1312. 2012. View Article : Google Scholar : PubMed/NCBI
27	Palsamy P and Subramanian S: Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling. Biochim Biophys Acta. 1812:719–731. 2011. View Article : Google Scholar : PubMed/NCBI
28	Do Amaral CL, Francescato HD, Coimbra TM, Costa RS, Darin JD, Antunes LM and Bianchi Mde L: Resveratrol attenuates cisplatin-induced nephrotoxicity in rats. Arch Toxicol. 82:363–370. 2008. View Article : Google Scholar
29	Holthoff JH, Wang Z, Seely KA, Gokden N and Mayeux PR: Resveratrol improves renal microcirculation, protects the tubular epithelium, and prolongs survival in a mouse model of sepsis-induced acute kidney injury. Kidney Int. 81:370–378. 2012. View Article : Google Scholar :
30	Liu FC, Tsai HI and Yu HP: Organ-Protective effects of red wine extract, resveratrol, in oxidative stress-mediated reperfusion injury. Oxid Med Cell Longev. 2015:5686342015. View Article : Google Scholar : PubMed/NCBI
31	Zhang B, Ramesh G, Norbury CC and Reeves WB: Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int. 72:37–44. 2007. View Article : Google Scholar : PubMed/NCBI
32	Li H, Zhu H, Xu CJ and Yuan J: Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 94:491–501. 1998. View Article : Google Scholar : PubMed/NCBI
33	Budihardjo I, Oliver H, Lutter M, Luo X and Wang X: Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol. 15:269–290. 1999. View Article : Google Scholar : PubMed/NCBI
34	Schug ZT, Gonzalvez F, Houtkooper RH, Vaz FM and Gottlieb E: BID is cleaved by caspase-8 within a native complex on the mitochondrial membrane. Cell Death Differ. 18:538–548. 2011. View Article : Google Scholar :
35	Ott M, Norberg E, Zhivotovsky B and Orrenius S: Mitochondrial targeting of tBid/Bax: A role for the TOM complex? Cell Death Differ. 16:1075–1082. 2009. View Article : Google Scholar : PubMed/NCBI
36	Korsmeyer SJ, Wei MC, Saito M, Weiler S, Oh KJ and Schlesinger PH: Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ. 7:1166–1173. 2000. View Article : Google Scholar